From Bench to Bedside: Discovery of the First FDA‐ Approved Antibody Therapeutic for Migraine
- 3:00 pm on Tuesday, October 13, 2020
- 4:00 pm on Tuesday, October 13, 2020
- Virtual via Zoom
This seminar is part of the Amgen Biotech Series open to students, trainees, and scholars. We will discuss the path of Aimovig (erenumab), a first‐in‐class antibody therapeutic for prevention of migraine, from early discovery through development to delivery to patients.